Table 2.
Performance Measures, Quality Measures, and Mortality Stratified by Reperfusion Strategy
| Measurement/Treatment | Overall [n = 5339] | PPCI [n = 2285] | Thrombolysis [n = 255] | None [n = 2799] | P Value |
|---|---|---|---|---|---|
| Early medical therapy, no. % | |||||
| Aspirin within <24 hours | 4365 (93.4) | 2026 (96.1) | 209 (94.9) | 2130 (90.9) | <0.001 |
| β‐Blockers within <24 hours | 3526 (86.9) | 1619 (90.4) | 177 (86.3) | 1730 (83.9) | <0.001 |
| Timelines of reperfusion | |||||
| DTN ≤ 30 minutes, % | N/A | N/A | 56 (21.9) | N/A | |
| DTB ≤ 90 minutes, % | N/A | 828 (36.2) | N/A | N/A | |
| DTN time, median (25th–75th), min | N/A | N/A | 54.5 (28.0–83.0) | N/A | |
| DTB time, median (25th–75th), min | N/A | 90.0 (63.0–135.0) | N/A | N/A | |
| Surgical revascularization, no. % | |||||
| CABG | 208 (4.8) | 33 (1.4) | 7 (4.7) | 168 (8.8) | <0.001 |
| Discharge medications, no. % | |||||
| ACEI/ARB in documented LVSD | 880 (78.9) | 390 (85.3) | 35 (76.1) | 455 (74.4) | <0.001 |
| ASA | 3672 (95.0) | 1889 (97.8) | 176 (98.9) | 1607 (91.5) | <0.001 |
| β‐Blockers | 3529 (94.3) | 1778 (96.8) | 168 (94.3) | 1583 (91.5) | <0.001 |
| Statins | 3109 (75.9) | 1735 (87.7) | 141 (71.2) | 1233 (64.3) | <0.001 |
| Clopidogrel | 2509 (67.8) | 1665 (91.7) | 127 (70.6) | 717 (42.1) | <0.001 |
| Other QCA measures, no. % | |||||
| Weight management | 1371 (77.8) | 830 (84.4) | 65 (69.2) | 476 (69.5) | <0.001 |
| Diabetes treatment | 291 (82.4) | 155 (86.1) | 9 (81.8) | 127 (78.4) | 0.1739 |
| Diabetes teaching | 29 (8.2) | 12 (6.7) | 1 (9.1) | 16 (9.9) | 0.5562 |
| Smoking cessation | 228 (80.9) | 129 (87.8) | 12 (66.7) | 87 (74.7) | 0.0067 |
| Blood pressure control | 2935 (79.1) | 1438 (81.1) | 148 (82.7) | 1349 (76.7) | 0.0026 |
| Cardiac rehabilitation | 3242 (77.1) | 1741 (86.2) | 137 (68.8) | 1364 (68.7) | <0.001 |
| In‐hospital mortality, no. % | 929 (17.4) | 226 (9.9) | 49 (19.2) | 654 (23.4) | <0.001 |
| LOS, median (25th–75th), d | 5 (3‐7) | 4 (3‐7) | 5 (3‐8) | 5 (3‐8) | 0.0045 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker; CABG, coronary artery bypass graft; DTB, door‐to‐balloon; DTN, door‐to‐needle; LOS, length of stay; LVSD, left ventricular systolic dysfunction; N/A, not applicable; QCA, quality control assessment.